Last year’s robust deal-making environment, high-value M&As, increasing financings and a supportive public market has set the stage for continued med-tech enthusiasm among investors and partners in 2020.
Regulatory decisions affecting biopharma products in development, including approvals, recommendations, rejections and the granting of regulatory pathways in December 2019.
SAN FRANCISCO – Pacing the stage at this year's China Showcase Saturday, Chinabio CEO Greg Scott sounded a touch disappointed. Last year lacked the kind of record-breaking stats he likes to punctuate with iconic explosions, a common image in his widely valued China health care talks. "Simply stated, business is continuing as normal," he said.
Whether the dealmaking momentum of 2019 will continue into 2020 is at the mercy of several uncertainties, not the least of which is the outcome of a U.S. presidential election and continued debates over drug pricing and other legislative issues affecting the industry.
RSS
